Looking to publish in Cancer Science? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowCancer Science is one of the oldest oncology journals in the world and has stimulated cancer research since 1907. It publishes research on molecular mechanisms of cancer development, with emphasis on innovative cancer treatment including molecular targeted therapy and immunotherapy based on genomic abnormalities of individual cancers and the tumor microenvironment.
Looking to publish in Cancer Science? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Cancer Science accepts the following article types. Click on an article type to view submission instructions.
Original Article
Review Article
Report
Case Report
Letter To The Editor
Recent Publications
Transporter‐Associated Therapeutic Efficacy of an SMVT ‐Targeted Boron Carrier in Boron Neutron Capture Therapy
Kenichiro Eza, Kohei Tsujino, Rina Shidoh‐Kazuki, Yoshiki Fujikawa, Hideki Kashiwagi, Gen Futamura, Ryo Hiramatsu, Toshihiro Takami, Masahiko Wanibuchi, Naonori Hu, Hiroki Tanaka, Minoru Suzuki, Kai Nishimura, Shota Tanaka, Hiroyuki Nakamura, Shinji Kawabata
Ketogenic Diet and β‐Hydroxybutyrate Suppress Bladder Cancer Growth and Enhance Anti‐ PD ‐ L1 Immunotherapy Efficacy
Yuan Zeng, Gangli Gu, Lin Yang, Bohao Fan, Haochen Cui, Lei Yan, Zhao Liu
Bile‐Derived Exosomal miR ‐196a/‐196b as Diagnostic Biomarkers Associated With Tumor Progression in Biliary Tract Cancer
Naotaka Kugiyama, Katsuya Nagaoka, Takehisa Watanabe, Michihiro Yoshida, Tadashi Toyohara, Cheng Pan, Kenyu Hashimoto, Fumiya Otsuka, Shinya Ushijima, Yukiko Uramoto, Hajime Iwasaki, Motohiro Yoshinari, Shunpei Hashigo, Kazuki Hayashi, Itaru Naitoh, Fumihiro Okumura, Hiromu Kondo, Kaiki Anbe, Hiromitsu Hayashi, Yoshihiro Komohara, Yasuhito Tanaka
Combined MEK1/2 and Autophagy Inhibition Suppresses Tumor Growth via STING‐Mediated Type I Interferon Response in iCCA
Chengqiang Sun, Zheng Gao, Enfu Dong, Liangxia Ding, Shanru Feng, Jiafeng Chen, Pascal Kwangwari, Yinghong Shi, Weiren Liu, Xin Zhang, Ao Huang, Jian Zhou, Sheng Wang, Jia Fan, Xiutao Fu, ZhenBin Ding
Ezh2 Inhibits the Differentiation of Short‐Lived Effector CD8 + T Cells and Promotes T Cell‐Dependent Antitumor Immunity
Kenji Takagi, Junpei Suzuki, Yuko Matsuoka, Makoto Kuwahara, Taro Oshikiri, Masakatsu Yamashita
Frequently asked questions
How long does it take to publish?
Submission to first decision (median): 8 days; submission to acceptance (median): 116 days; acceptance to publication (median): 14 days.
Reformat to Cancer Science using Livewrite PremiumIs a cover letter required?
A covering letter should be attached. It should declare exclusive submission, confirm all authors meet authorship criteria and agree with the manuscript, provide corresponding author contact details, summarize salient and novel findings, specify one subject category, explain any word-count overage, include rationale for multiple corresponding authors if applicable, and confirm patient consent for Case Reports.
Reformat to Cancer Science using Livewrite PremiumWhat are the publication costs?
APC: $2,600 USD / £1,650 GBP / €2,350 EUR. Society members receive 61% off, Associate Editors receive 20% off, and Meeting Report articles are waived.
Reformat to Cancer Science using Livewrite Premium